<DOC>
	<DOCNO>NCT00549107</DOCNO>
	<brief_summary>Pediatric patient , especially infant undergo open heart surgery predictable fall cardiac index 6 18 hour surgery , so-called low cardiac output syndrome ( LCOS ) . Patients , LCOS require monitoring , medication longer stay intensive care unit . To prevent LCOS phosphodiesterase inhibitor milrinone routinely use first 24 hour surgery . Levosimendan , calcium- sensitizer improve cardiac muscle contractile force , vascular smooth muscle relaxation coronary blood flow calcium sensitization myocardial contractile filament open potassium channel without increase oxygen consumption heart muscle cell . As myocardium infant calcium dependent later life , levosimendan special benefit age group . The purpose study investigate whether levosimendan superior milrinone prevent LCOS infant corrective open heart surgery .</brief_summary>
	<brief_title>Prophylactic Use Levosimendan Versus Milrinone Open Heart Surgery Infants</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cardiac Output , Low</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<mesh_term>Milrinone</mesh_term>
	<criteria>Age young one year corrective open heart surgery biventricular repair , except tetralogy fallot Missing write consent parent Weight le 3 kg preoperative LCOS gestational age le 36 week preexist renal failure preexist thrombopenia preoperative cardiopulmonary resuscitation preoperative use milrinone levosimendan</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>low cardiac output syndrome</keyword>
	<keyword>open heart surgery</keyword>
	<keyword>infant</keyword>
	<keyword>Low cardiac output syndrome infant undergo corrective open heart surgery</keyword>
</DOC>